Carboxylic Acid, Percarboxylic Acid, Or Salt Thereof (e.g., Peracetic Acid, Etc.) Patents (Class 514/557)
  • Patent number: 11351153
    Abstract: An antimicrobial composition containing a synergistic combination of an imidazole antifungal agent and activated creatinine is provided, wherein the imidazole antifungal agent represents in the range of about 0.5 mol % to about 30 mol % of the combination of the antifungal agent and the activated creatinine in the composition. Methods for treating bacterial infections, fungal infections, viral infections, and wounds are also provided, as are other methods of use, including methods for disinfecting inert surfaces, methods for preserving food products, and methods for treating plants. In addition, the invention provides a method for enhancing the antifungal effect of an imidazole antifungal agent as well as a method for enhancing the antibacterial effect of activated creatinine. Compositions and methods involving use of activated 2-amino-imidazol-4-one analogs other than activated creatinine are also provided.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: June 7, 2022
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Thomas McDonald, Steven M. Tracy
  • Patent number: 11298330
    Abstract: The present invention provides a method of administering magnesium threonate to a subject in need of supplementing magnesium. At least a portion of magnesium (Mg) and threonate (T) is present in a salt form of MgT2. The method may comprise administration of magnesium threonate at two different time points per day. The method may comprise administering, at a first time point, a first oral dosage form comprising magnesium threonate. The method may comprise administering, at a second time point, a combination of the first oral dosage form and a second oral dosage form comprising magnesium threonate. The first and second oral dosage forms may exhibit different dissolution profiles in a dissolution medium.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 12, 2022
    Assignee: Neurocentria, Inc.
    Inventors: Guosong Liu, Fei Mao, Jason Weinger
  • Patent number: 11278567
    Abstract: Methods for modifying neuronal functional activity and/or treating a neurological disorder by using agents that raise neuronal intracellular concentration of magnesium are disclosed. Also provided herein are methods of determining the amenability of an individual to treatment for a neurological disorder, by measuring changes in intracellular magnesium concentration.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 22, 2022
    Assignee: Neurocentria, Inc.
    Inventors: Guosong Liu, Hang Zhou
  • Patent number: 11203613
    Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I?): where the substituents R, R1, R3 R4, R?, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: December 21, 2021
    Inventors: Gang Lin, Carl Nathan, Wenhu Zhan, Trevor Morgan, Ryoma Hara, Toshihiro Imaeda, Rei Okamoto, Kenjiro Sato, Kazuyoshi Aso, Tzu-Tshin Wong, Michael A. Foley
  • Patent number: 11185518
    Abstract: Ketogenic compositions include a mixture of optically pure S-beta-hydroxybutyrate salts and acid(s) or non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contains from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 30, 2021
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 11179350
    Abstract: An anti-inflammatory and anti-oxidative nutraceutical composition containing C60 fullerene, a COX-2 inhibitor, and a medium chain triglyceride. The combined use of C60 and COX-2 inhibitor has unexpected benefits in promoting health, including synergistic effects in fighting cancer, slowing aging, and in some cases, reversing aging. Advantageously, Nigella sativa (“black seed”) oil is used to provide both medium chain triglycerides and COX-2 inhibitors.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: November 23, 2021
    Inventor: Max Champie
  • Patent number: 11162006
    Abstract: The present invention provides an adhesive, high water content gel that does not cause a heat generation problem even when used as a patient plate for electrosurgical units through which high current flows and that is excellent in adhesion, as well as an electrode pad including the gel. The present invention relates to an adhesive, high water content hydrogel containing a polymer matrix that includes a copolymer of a polymerizable monomer and a crosslinkable monomer, water, a polyhydric alcohol, an electrolyte, polyacrylic acid, and polyvinyl alcohol, the hydrogel containing, based on 100% by weight of the total hydrogel, 40-70% by weight of water, 1.0-5.0% by weight of polyacrylic acid, and 0.5-5.0% by weight of polyvinyl alcohol, and being produced by copolymerization. An electrode pad is also obtained by coating a conductive layer formed on a base film with the adhesive, high water content hydrogel.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: November 2, 2021
    Assignee: SEKISUI PLASTICS CO., LTD.
    Inventor: Hiroyoshi Tanaka
  • Patent number: 11147270
    Abstract: A pesticide formulation preserves an effective concentration of an active form over time. For example, the active form may be generated over time as it is removed from the system. For example, Calcium Formate may be transformed to an active form of Formic Acid. For example, modulator such as citric acid may facilitate driving the generative reaction forward, for example by removing Calcium form the solution. Optionally Boric acid may be added to the formulation. The formulation may be applied dry and/or wet to the organisms and/or their living space.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: October 19, 2021
    Inventor: Ido Eco Ofek
  • Patent number: 11103470
    Abstract: Ketogenic compositions include a non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the R-enantiomer. The compositions are enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer to provide alternative benefits. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 50.5% to 99.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: August 31, 2021
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 11076590
    Abstract: Some embodiments may be of spearfishing apparatus fitted with at least one magnet configured to repel sharks away from the spearfishing apparatus. The spearfishing apparatus may be one or more of: a spearfishing shaft, a spearfishing tip, and/or a spearfishing gun. Some embodiments may be of personal floatation devices (PFDs) fitted with at least one magnet configured to repel sharks away from the PFDs. Some PFDs may be fitted with a tethered drop-down magnetic apparatus to protect lower extremities of a wearer of such PFDs. Such magnets may be electromagnets powered by batteries in some embodiments.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: August 3, 2021
    Inventor: Brian Chase Watson
  • Patent number: 11065217
    Abstract: The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: July 20, 2021
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Ira C. Spector, Mark A. Feitelson, Alla Arzumanyan
  • Patent number: 11045525
    Abstract: The present disclosure provides, in one embodiment, a method of treating or preventing an ID2 protein-related disease in a patient at risk of developing or having such a disease by administering to the patient a composition in an amount and for a time sufficient to increase degradation of HIF? in a cell affected by the ID2 protein-related disease in the patent and/or to decrease half-life of HIF? in the cell affected by the ID2 protein-related disease in the patient, as compared to an untreated cell affected by the ID2 protein-related disease.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: June 29, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Antonio Iavarone, Anna Lasorella
  • Patent number: 11045588
    Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 29, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Patent number: 11035631
    Abstract: A countermass liquid for a shoulder launched propulsion system that has low corrosivity, high density, low viscosity, and a constant viscosity as a function of temperature. Upon function of the shoulder launched propulsion system, the countermass liquid may be expelled through the breach end of the shoulder launched propulsion system by expanding propellant gas. The countermass liquid may be an organic salt selected from the group consisting of at least one or more of cesium formate and potassium formate.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: June 15, 2021
    Assignee: Nammo Defense Systems Inc.
    Inventors: Dominic Jezierski, Jerry Lambert, Harry Blomquist, Stephen Joseph Early, Bill Goodwin
  • Patent number: 11020362
    Abstract: Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts and beta-hydroxybutyric acid are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB composition is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes beta-hydroxybutyric acid and a plurality of BHB salts selected from sodium, potassium, calcium, and magnesium. The BHB composition may include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long chain fatty acid source, vitamin D3, flavorant, or other excipient.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 1, 2021
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 11015151
    Abstract: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: May 25, 2021
    Assignee: Ecolab USA Inc.
    Inventors: Junzhong Li, Richard K. Staub, David D. McSherry, Keith G. LaScotte, Steven J. Lange, Frank Everts
  • Patent number: 10973786
    Abstract: Beta-hydroxybutyrate (BHB) mixed salts are formulated to induce or sustain ketosis in a subject. The BHB mixed salts provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. BHB mixed salt compositions include two, three or four of sodium BHB, potassium BHB, calcium BHB, or magnesium BHB. BHB mixed salt compositions include R-BHB and/or S-BHB, such as enriched with either R-BHB or S-BHB. BHB mixed salt compositions may include BHB mixed salts and beta-hydroxybutyric acid. BHB mixed salts may be provided as or mixed with a dietetically or pharmaceutically acceptable carrier. BHB mixed salt compositions can be a solid, such as a powder, or a liquid, such as a beverage. A mixed salt-acid composition is particularly well-suited for flavored beverages.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 13, 2021
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 10940140
    Abstract: The present invention relates to a pharmaceutical composition or a kit comprising, a first substance capable of raising intracellular cAMP levels, and a second substance capable of modulating intracellular calcium concentration. Likewise, the present invention relates to methods of treating patients suffering from autism spectrum disorder (ASD) phenotype 1 by administering an effective amount of a substance capable of raising intracellular cAMP levels and, optionally, an effective amount of a substance capable of modulating intracellular calcium concentration.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: March 9, 2021
    Assignee: Stalicla S.A.
    Inventor: Lynn Durham
  • Patent number: 10899707
    Abstract: The present invention relates generally to methods for forming peroxyformic acid, comprising contacting formic acid with hydrogen peroxide. The methods for forming peroxyformic acid can include adding formic acid with a relatively lower concentration of hydrogen peroxide, or adding formic acid to a peroxycarboxylic acid composition or forming composition to react with hydrogen peroxide in the compositions. The present invention also relates to peroxyformic acid formed by the above methods. The present invention further relates to the uses of peroxyformic acid for treating a variety of targets, e.g., target water, including target water used in connection with oil- and gas-field operations. The present invention further relates to methods for reducing or removing H2S or iron sulfide in the treated water source, improving clarity of the treated water source, or reducing the total dissolved oxygen or corrosion in the treated water source, using peroxyformic acid, including peroxyformic acid generated in situ.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: January 26, 2021
    Assignee: Ecolab USA Inc.
    Inventors: Ramakrishnan Balasubramanian, Junzhong Li, Richard Staub, Victor Keasler, Brian Bennett, Allison Brewster
  • Patent number: 10828303
    Abstract: An object of this invention is to provide a composition for preventing and/or treating neurodegenerative diseases and cerebral infarction, and a composition for ameliorating learning disorders. Provided is a composition comprising a combination of a TRH analog and arundic acid.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: November 10, 2020
    Assignee: BRIVENTION PHARMACEUTICAL (SHANGHAI) INC.
    Inventors: Michio Yamamura, Narito Tateishi
  • Patent number: 10772856
    Abstract: The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to enhance or promote lipolysis, increase adipocyte fat oxidation, induce adipocyte and muscle mitochondrial biogenesis, increase energy expenditure, decrease total body weight and increase body fat loss.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: September 15, 2020
    Assignee: Metabolic Technologies, Inc.
    Inventors: John Rathmacher, Naji Abumrad, Shawn Baier
  • Patent number: 10729668
    Abstract: Disclosed herein are methods for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the lifespan of a subject which comprise administering to the subject one or more ketobutyrate compounds and compositions thereof.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: August 4, 2020
    Assignee: The Regents of the University of California
    Inventors: Jing Huang, Randall M. Chin, Xudong Fu, Heejun Hwang, Karen Reue, Laurent Vergnes, Meisheng Jiang, Brett E. Lomenick, Xiang Yin, Mansoureh Eghbali, Jingyuan Li, Samuel Wheeler French, Ronik Khachatoorian
  • Patent number: 10716857
    Abstract: The present invention concerns a pharmaceutical composition comprising formic acid and at least one C1-C4 alkyl ester of lactic acid, malic acid, tartaric acid, citric acid, preferably ethyl lactate, for the topical treatment of warts.
    Type: Grant
    Filed: May 28, 2012
    Date of Patent: July 21, 2020
    Assignee: ABBEX AB
    Inventor: Flemming Licht
  • Patent number: 10668045
    Abstract: An example method of treating a medical issue includes applying a composition to a skin area corresponding to a location afflicted with the medical issue. The composition includes a blend of Cannabidiol (CBD) oil and Cannabinol (CBN) oil fortified with curcumin from turmeric, Boswellic acid, and polycyclic terpenes from Boswellia serrata. The medical issue includes at least one of osteoarthritis, joint pain associated with natural causes or injury, reduced joint function and flexibility after injury or other causes, and photo-aging. A composition including a blend of pure CBD oil and CBN oil fortified with curcumin from turmeric and Boswellic acid along with polycyclic terpenes from Boswellia serrata is also disclosed.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: June 2, 2020
    Inventors: V. Hari, John Stockwell
  • Patent number: 10660869
    Abstract: The present invention relates to a lactate powder, more particularly a lactate powder having a lactate content of at least 20 wt. % and a water content of less than 3.5 wt. %, said powder comprising calcium cations as well as sodium cations. According to the invention, a calcium lactate powder combining high stability with excellent water dissolution properties can be obtained even though anhydrous calcium lactate represents the bulk of the powder if the powder additionally contains a certain amount of sodium lactate. The inventors have found that the presence of sodium lactate greatly improves the dissolution behavior of the anhydrous calcium lactate while maintaining the storage stability of the powder. The present inventors also established that the dissolution behavior of the powder can be further improved by the addition of a fast-dissolving carbohydrate material.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: May 26, 2020
    Assignee: PURAC BIOCHEM B.V.
    Inventors: Kees Van Der Voort Maarschalk, Heny Kusumawardani
  • Patent number: 10632092
    Abstract: The invention provides methods and compositions for reducing the percentage of body fat in an animal or human and increasing the level of adiponectin in an animal or human. Such methods include administering to an animal or human sufficient levels of a compound comprising a tri blend of HPMC (K15, K100, and K200) and myristic fatty acid.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: April 28, 2020
    Assignee: First Fruits Business Ministry, LLC
    Inventors: Roger J. Catarino, William D. Kuhne
  • Patent number: 10617713
    Abstract: Methods for modifying neuronal functional activity and/or treating a neurological disorder by using agents that raise neuronal intracellular concentration of magnesium are disclosed. Also provided herein are methods of determining the amenability of an individual to treatment for a neurological disorder, by measuring changes in intracellular magnesium concentration.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: April 14, 2020
    Assignee: Neurocentria, Inc.
    Inventors: Guosong Liu, Hang Zhou
  • Patent number: 10617703
    Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 14, 2020
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 10596132
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: March 24, 2020
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 10588564
    Abstract: The disclosure concerns a medical kit arranged with componentry for fluorescein sodium (FNa)-based diagnosis and trichloroacetic acid (TCA)-based treatment of neoplastic tissue, and related methods for utilizing aspects of the medical kit.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: March 17, 2020
    Inventors: Sudabeh Moein, Frederick J. Zustak
  • Patent number: 10588878
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 17, 2020
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 10583120
    Abstract: A pharmaceutical composition or dietary supplement having a muscle-relaxant and anti-inflammatory activity is described, which is effective in the treatment of muscle, bone, articular and tendon pathologies, comprising, as active ingredients, a combination of magnesium, at least one ketoboswellic acid and L-tryptophan.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: March 10, 2020
    Assignee: Kolinpharma S.p.A.
    Inventors: Domenico Bijno, Carmine Di Vincenzo, Emanuele Lusenti, Alberto Martina, Ritapaola Petrelli
  • Patent number: 10518113
    Abstract: An exfoliating dentifrice composition is described that contains a plurality of granules and an orally acceptable vehicle. The granules include at least one polymeric binding agent. The composition includes at least one abrasive agent having an average particle diameter of 0.01 mm to 4 mm. Also included are methods of exfoliating an oral cavity soft tissue by use of the composition.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: December 31, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Thomas Boyd, Evangelia Arvanitidou, Joe Vazquez, Ying Yang, Qing Claire He, Mary Horchos
  • Patent number: 10471034
    Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: November 12, 2019
    Assignee: AXCELLA HEALTH INC.
    Inventors: Michael Hamill, Raffi Afeyan, Chung-Wei Lee, Harry Luithardt
  • Patent number: 10456472
    Abstract: The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: October 29, 2019
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: David Gschneidner, Stephen V. Pusztay
  • Patent number: 10405545
    Abstract: Compositions and methods for the disinfection of surfaces are provided. The compositions include an alcohol and a peracid. The disinfectant composition is characterized by a pH of no more than about 5. Broad spectrum efficacy is achieved, and synergistic activity is exhibited against bacterial and fungal spores, including Clostridium difficile spores. The compositions and methods are also useful against conformationally altered prions, bacteria, fungi, and viruses.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: September 10, 2019
    Assignee: GOJO Industries, Inc.
    Inventors: James Edmund Bingham, Christopher M. Fricker, Michael J. Dolan
  • Patent number: 10357466
    Abstract: The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ˜95° F. to ˜98.5° F. (˜35° C. to ˜36.7° C.) to mitigate and delay the early onset and progression of fatal disease processes associated with premature aging, such as those characteristic of progeria (Hutchinson-Gilford Progeria Syndrome, HGPS), Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), Werner syndrome, and other rare disorders characterized by premature aging, and to prolong the shortened lifespan of children afflicted with these diseases. Short-term chronic administration of the pharmaceutical treatments to a person suffering from mild concussion may also have value in ameliorating neurological damage/symptoms associated with mild concussion. Chronic administration of the pharmacological treatments may also have value in normal human populations or in high-risk human populations.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: July 23, 2019
    Inventors: Stephen J. Petti, Samn Raffaniello Petti
  • Patent number: 10350257
    Abstract: The present invention provides a pharmaceutical or health functional food containing, as an active ingredient, a complex extract of Crataegi Fructus and Citri Pericarpium. The complex extract has the effects of reducing body weight and lipids in blood vessels.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: July 16, 2019
    Assignee: NEUMED
    Inventors: Juyeon Park, Dong Wook Lim, Mikyung Song
  • Patent number: 10328039
    Abstract: A process for producing a pharmaceutical lozenge formulation comprising the steps of: (a) providing a liquid composition comprising a salt of a non-steroidal anti-inflammatory drug (NSAID salt) and a solvent system, (b) providing a molten lozenge-forming composition, (c) mixing the liquid composition with the molten lozenge-forming composition, and, (d) forming the resulting mixture into lozenges each containing a therapeutically effective amount of said NSAID salt/NSAID mixture. The present application discloses the corresponding NSAID-containing lozenge compositions and their use for the manufacture of a medicament for treating sore throat.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: June 25, 2019
    Assignee: RECKIIT BENCKISER HEALTHCARE (UK) LIMITED
    Inventors: Kirsty Sawicka, Jasmine Takhar, Paul Marshall, Michael Fanfarillo
  • Patent number: 10322098
    Abstract: The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 18, 2019
    Assignee: STAYBLE THERAPEUTICS AB
    Inventor: Kjell Olmarker
  • Patent number: 10323218
    Abstract: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: June 18, 2019
    Assignee: Ecolab USA Inc.
    Inventors: Junzhong Li, Richard K. Staub, David D. McSherry, Keith G. Lascotte, Steven J. Lange, Frank Everts
  • Patent number: 10307406
    Abstract: In an effort to discover therapies for treating diseases caused by EBV, a novel screening assay for identifying compounds that reactivate EBV latent infection and a family of small molecules based on a tetrahydrocarboline backbone were discovered. Specifically, the compounds have the structure of the formula (I), wherein R1-R11 are defined herein and activate/reactivate EBV in a variety of cell types in a patient and are, therefore, useful in preventing or treating EBV-positive cancer, optionally with an anti-viral agent. In screening these compounds, novel compositions, EBV-positive cell lines, and methods are provided.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: June 4, 2019
    Assignees: The Wistar Institute of Anatomy and Biology, Drexel University
    Inventors: Paul M. Lieberman, Nadezhda Tikhmyanova-Eckert, Joseph M. Salvino
  • Patent number: 10301263
    Abstract: The invention relates to pharmaceutical uses of compounds of formula (II). Particular aspects of the invention relate to the use of those compounds in treating, preventing or ameliorating a seizure-related disorder, bipolar disorder, mania, migraine, Alzheimer's disease, Parkinson's disease or stroke.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: May 28, 2019
    Assignee: Royal Holloway and Bedford New College
    Inventors: Robin Williams, Matthew Walker
  • Patent number: 10265289
    Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating melanoma and a pharmaceutical composition comprising chlorogenic acid and used for treating melanoma.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: April 23, 2019
    Assignee: SICHU JIUZHANG BOPLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.
    Inventors: Jie Zhang, Xiaoguang Chen, Jun Huang, Wang Huang
  • Patent number: 10233149
    Abstract: The present invention relates generally to methods for forming peroxyformic acid, comprising contacting formic acid with hydrogen peroxide. The methods for forming peroxyformic acid can include adding formic acid with a relatively lower concentration of hydrogen peroxide, or adding formic acid to a peroxycarboxylic acid composition or forming composition to react with hydrogen peroxide in the compositions. The present invention also relates to peroxyformic acid formed by the above methods. The present invention further relates to the uses of peroxyformic acid for treating a variety of targets, e.g., target water, including target water used in connection with oil- and gas-field operations. The present invention further relates to methods for reducing or removing H2S or iron sulfide in the treated water source, improving clarity of the treated water source, or reducing the total dissolved oxygen or corrosion in the treated water source, using peroxyformic acid, including peroxyformic acid generated in situ.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: March 19, 2019
    Assignee: ECOLAB USA INC.
    Inventors: Ramakrishnan Balasubramanian, Junzhong Li, Richard Staub, Victor Keasler, Brian Bennett, Allison Brewster
  • Patent number: 10194656
    Abstract: Embodiments herein relate to animal feed preservatives including byproducts containing levulinic acid and methods of making and using the same. In an embodiment, a method of making an animal feed preservative is included. The method can include obtaining an acidic byproduct of a manufacturing process. The acidic byproduct can include at least about 1% by weight levulinic acid or a salt thereof. The method can further include mixing the acidic byproduct with a base to form the animal feed preservative. The animal feed preservative can include at least about 5 wt. % of the acid byproduct. In various embodiments, a method of reducing the amount of mycotoxins formed in an animal feed product during storage is included. In various embodiments, an animal feed preservative or supplement is included. Other embodiments are also included herein.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: February 5, 2019
    Assignee: Hawkins, Inc.
    Inventors: Theodore R. Stern, Stephen G. Campano, Gary Carl Larson
  • Patent number: 10168125
    Abstract: A composition for deterring intruders includes propionic acid, ammonia and water. A content of water in the composition is at least approximately 60% by weight. A system for spraying a composition comprises a nozzle configured to spray the composition in an area inside a building. The composition comprises propionic acid, ammonia and water. A content of water in the composition is at least approximately 60% by weight.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: January 1, 2019
    Assignee: CROTEGA, LLC
    Inventors: Jody Allen Crowe, Oliver D. Nichols
  • Patent number: 10154974
    Abstract: The present disclosure provides methods for treating or preventing malaria by administration of abscisic acid, analogs or pharmaceutical salts thereof to a mammalian subject infected with or at risk of exposure to Plasmodium. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasitemia and gametocytemia in a mammalian subject and/or reducing transmission of Plasmodium by a mosquito vector.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: December 18, 2018
    Assignee: The Regents Of The University Of California
    Inventors: Shirley Luckhart, Elizabeth K. K. Glennon
  • Patent number: 10149610
    Abstract: Systems and methods to improve the detection and classification of inflammation in the eye are presented. The inflammatory markers in image data can be graded by comparing identified and extracted characteristics from the images with characteristics derived from a set of images of eyes from a general population of subjects. The image data can be divided into sub-regions for analysis to better isolate the true inflammatory markers from the impacts of cataracts or other opacities. In another embodiment, the location of an imaging beam can be controlled to minimize the impact of lens opacities from the collected data used to analyze the inflammation state of an eye.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: December 11, 2018
    Assignee: CARL ZEISS MEDITEC, INC.
    Inventors: Harihar Narasimha-Iyer, Mary K. Durbin
  • Patent number: RE48854
    Abstract: The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of using the same for improving the health and survival of animal offspring.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: December 21, 2021
    Assignee: VALENT BIOSCIENCES LLC
    Inventors: Maria Pilar Herrero, Warren E. Shafer